-
Je něco špatně v tomto záznamu ?
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men
R. Ornello, C. Baraldi, S. Guerzoni, G. Lambru, M. Fuccaro, B. Raffaelli, A. Gendolla, P. Barbanti, C. Aurilia, S. Cevoli, V. Favoni, F. Vernieri, C. Altamura, A. Russo, M. Silvestro, E. Dalla Valle, A. Mancioli, A. Ranieri, G. Alfieri, N....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
- Publikační typ
- časopisecké články MeSH
Objective: We reported gender-specific data on the efficacy and safety of erenumab, a monoclonal antibody antagonizing the calcitonin gene-related peptide (CGRP) receptor. Methods: Our pooled patient-level analysis of real-world data included patients treated with erenumab and followed up for 12 weeks. We considered the following outcomes at weeks 9-12 of treatment compared with baseline: 0-29%, 30-49%, 50-75%, and ≥75% responder rates, according to the decrease in monthly headache days (MHDs), rate of treatment stopping, change in MHDs, monthly migraine days (MMDs), monthly days of acute medication and triptan use, and Headache Impact Test-6 (HIT-6) score from baseline to weeks 9-12. Outcomes were compared between men and women by the chi-squared test or t-test, as appropriate. An analysis of covariance (ANCOVA) was performed to identify factors influencing the efficacy outcomes. Results: We included 1,410 patients from 16 centers, of which 256 (18.2%) were men. Men were older than women and had a lower number of MHDs at baseline. At weeks 9-12, compared with baseline, 46 (18.0%) men had a ≥75% response, 75 (29.3%) had a 50-74% response, 35 (13.7%) had a 30-49% response, and 86 (33.6%) had a 0-29% response, while 14 (5.5%) stopped the treatment. The corresponding numbers for women were 220 (19.1%), 314 (27.2%), 139 (12.0%), 402 (34.8%), and 79 (6.8%). No gender difference was found in any of the outcomes. The ANCOVA showed that gender did not influence the efficacy of outcomes. Conclusion: We found that erenumab is equally safe and effective in men compared with women after 12 weeks.
Department of Neurology Alfred Health Melbourne VIC Australia
Department of Neurology Charité Universitätsmedizin Berlin Berlin Germany
Department of Neurology F Renzetti Hospital Chieti Italy
Department of Neurology G Mazzini Hospital Teramo Italy
Department of Neurology S Pio da Pietrelcina Hospital Chieti Italy
Department of Neurology West German Headache Center University Hospital Essen Essen Germany
Headache and Neurosonology Unit Policlinico Universitario Campus Bio Medico Rome Italy
Headache and Pain Unit Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Rome Italy
Headache Centre Division of Neurology and Stroke Unit A Cardarelli Hospital Naples Italy
Headache Centre Ospedale S Antonio Abate ASST Valle Olona Gallarate Italy
San Raffaele University Rome Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010441
- 003
- CZ-PrNML
- 005
- 20220425131830.0
- 007
- ta
- 008
- 220420s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fneur.2021.774341 $2 doi
- 035 __
- $a (PubMed)34975732
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Ornello, Raffaele $u Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy
- 245 10
- $a Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men / $c R. Ornello, C. Baraldi, S. Guerzoni, G. Lambru, M. Fuccaro, B. Raffaelli, A. Gendolla, P. Barbanti, C. Aurilia, S. Cevoli, V. Favoni, F. Vernieri, C. Altamura, A. Russo, M. Silvestro, E. Dalla Valle, A. Mancioli, A. Ranieri, G. Alfieri, N. Latysheva, E. Filatova, J. Talbot, S. Cheng, D. Holle, A. Scheffler, T. Nežádal, D. Čtrnáctá, J. Šípková, Z. Matoušová, L. Sette, A. Casalena, M. Maddestra, S. Viola, G. Affaitati, MA. Giamberardino, F. Pistoia, U. Reuter, S. Sacco
- 520 9_
- $a Objective: We reported gender-specific data on the efficacy and safety of erenumab, a monoclonal antibody antagonizing the calcitonin gene-related peptide (CGRP) receptor. Methods: Our pooled patient-level analysis of real-world data included patients treated with erenumab and followed up for 12 weeks. We considered the following outcomes at weeks 9-12 of treatment compared with baseline: 0-29%, 30-49%, 50-75%, and ≥75% responder rates, according to the decrease in monthly headache days (MHDs), rate of treatment stopping, change in MHDs, monthly migraine days (MMDs), monthly days of acute medication and triptan use, and Headache Impact Test-6 (HIT-6) score from baseline to weeks 9-12. Outcomes were compared between men and women by the chi-squared test or t-test, as appropriate. An analysis of covariance (ANCOVA) was performed to identify factors influencing the efficacy outcomes. Results: We included 1,410 patients from 16 centers, of which 256 (18.2%) were men. Men were older than women and had a lower number of MHDs at baseline. At weeks 9-12, compared with baseline, 46 (18.0%) men had a ≥75% response, 75 (29.3%) had a 50-74% response, 35 (13.7%) had a 30-49% response, and 86 (33.6%) had a 0-29% response, while 14 (5.5%) stopped the treatment. The corresponding numbers for women were 220 (19.1%), 314 (27.2%), 139 (12.0%), 402 (34.8%), and 79 (6.8%). No gender difference was found in any of the outcomes. The ANCOVA showed that gender did not influence the efficacy of outcomes. Conclusion: We found that erenumab is equally safe and effective in men compared with women after 12 weeks.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Baraldi, Carlo $u Department of Biomedical, Metabolic and Neural Sciences, School in Neurosciences, University of Modena and Reggio Emilia, Modena, Italy
- 700 1_
- $a Guerzoni, Simona $u Medical Toxicology - Headache and Drug Abuse Research Center, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
- 700 1_
- $a Lambru, Giorgio $u The Headache Service, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom
- 700 1_
- $a Fuccaro, Matteo $u The Headache Service, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom
- 700 1_
- $a Raffaelli, Bianca $u Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Gendolla, Astrid $u Praxis Gendolla, Essen, Germany
- 700 1_
- $a Barbanti, Piero $u Headache and Pain Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Rome, Italy $u San Raffaele University, Rome, Italy
- 700 1_
- $a Aurilia, Cinzia $u Headache and Pain Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Rome, Italy
- 700 1_
- $a Cevoli, Sabina $u Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
- 700 1_
- $a Favoni, Valentina $u Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
- 700 1_
- $a Vernieri, Fabrizio $u Headache and Neurosonology Unit, Policlinico Universitario Campus Bio-Medico, Rome, Italy
- 700 1_
- $a Altamura, Claudia $u Headache and Neurosonology Unit, Policlinico Universitario Campus Bio-Medico, Rome, Italy
- 700 1_
- $a Russo, Antonio $u Headache Center, Department of Medical, Surgical, Neurological, Metabolic, and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
- 700 1_
- $a Silvestro, Marcello $u Headache Center, Department of Medical, Surgical, Neurological, Metabolic, and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
- 700 1_
- $a Dalla Valle, Elisabetta $u Headache Centre, Ospedale S. Antonio Abate, ASST Valle Olona, Gallarate, Italy
- 700 1_
- $a Mancioli, Andrea $u Headache Centre, Ospedale S. Antonio Abate, ASST Valle Olona, Gallarate, Italy
- 700 1_
- $a Ranieri, Angelo $u Headache Centre, Division of Neurology and Stroke Unit, "A. Cardarelli" Hospital, Naples, Italy
- 700 1_
- $a Alfieri, Gennaro $u Headache Centre, Division of Neurology and Stroke Unit, "A. Cardarelli" Hospital, Naples, Italy
- 700 1_
- $a Latysheva, Nina $u Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
- 700 1_
- $a Filatova, Elena $u Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
- 700 1_
- $a Talbot, Jamie $u Southwest Neurology Audit and Research Group, Department of Neurology, Derriford Hospital, Plymouth, United Kingdom
- 700 1_
- $a Cheng, Shuli $u Department of Neurology, Alfred Health, Melbourne, VIC, Australia
- 700 1_
- $a Holle, Dagny $u Department of Neurology, West German Headache Center, University Hospital Essen, Essen, Germany
- 700 1_
- $a Scheffler, Armin $u Department of Neurology, West German Headache Center, University Hospital Essen, Essen, Germany
- 700 1_
- $a Nežádal, Tomáš $u Department of Neurology, Military University Hospital Prague, First Faculty of Medicine Charles University, Prague, Czechia
- 700 1_
- $a Čtrnáctá, Dana $u Department of Neurology, Military University Hospital Prague, First Faculty of Medicine Charles University, Prague, Czechia
- 700 1_
- $a Šípková, Jitka $u Department of Neurology, Military University Hospital Prague, First Faculty of Medicine Charles University, Prague, Czechia
- 700 1_
- $a Matoušová, Zuzana $u Department of Neurology, Motol University Hospital Prague, First Faculty of Medicine Charles University, Prague, Czechia
- 700 1_
- $a Sette, Lucia $u Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy
- 700 1_
- $a Casalena, Alfonsina $u Department of Neurology, "G. Mazzini" Hospital, Teramo, Italy
- 700 1_
- $a Maddestra, Maurizio $u Department of Neurology, "F. Renzetti" Hospital, Chieti, Italy
- 700 1_
- $a Viola, Stefano $u Department of Neurology, "S. Pio da Pietrelcina" Hospital, Chieti, Italy
- 700 1_
- $a Affaitati, Giannapia $u Headache Center, Geriatrics Clinic, Department of Medicine and Science of Aging and Center for Advanced Studies and Technology, G. D'Annunzio University, Chieti, Italy
- 700 1_
- $a Giamberardino, Maria Adele $u Headache Center, Geriatrics Clinic, Department of Medicine and Science of Aging and Center for Advanced Studies and Technology, G. D'Annunzio University, Chieti, Italy
- 700 1_
- $a Pistoia, Francesca $u Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy
- 700 1_
- $a Reuter, Uwe $u The Headache Service, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom $u Universitätsmedizin Greifswald, Greifswald, Germany
- 700 1_
- $a Sacco, Simona $u Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy
- 773 0_
- $w MED00174552 $t Frontiers in neurology $x 1664-2295 $g Roč. 12, č. - (2021), s. 774341
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34975732 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220420 $b ABA008
- 991 __
- $a 20220425131828 $b ABA008
- 999 __
- $a ind $b bmc $g 1784594 $s 1161639
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 12 $c - $d 774341 $e 20211216 $i 1664-2295 $m Frontiers in neurology $n Front. neurol. $x MED00174552
- LZP __
- $a Pubmed-20220420
